FOREWORD
It has been 12 years since the publication of the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) guideline for evaluation, classification, and stratification of chronic kidney disease (CKD). 1 While not a new medication, a new device, or a landmark clinical trial, this guideline publication perhaps had a greater impact on the diagnosis and management of people with CKD than anything else that has happened in nephrology in the first decade of the 21st century. But like much in medicine, new "discoveries"-medications, devices, or clinical practice guidelines-need a test of time to understand their risks, benefits, and overall place in the care of patients. As the KDOQI CKD guideline made its way into clinical practice, much changed; creatinine assays were standardized, laboratory reports changed, new International Classification of Diseases (ICD-9) codes were generated, new equations for the estimation of glomerular filtration rate (GFR) were developed, nephrologists and others began to speak a common language when it came to studying and taking care of those with CKD, and an explosion in CKDrelated research occurred. However, there was also concern that patients who did not have clinically meaningful kidney dysfunction were being identified as having a "disease," patients worried (stage 3 cancer is often life-threatening.stage 3 CKD cannot be much different), the inherent imprecision of formulas used to calculate estimated GFR (eGFR) for CKD classification was often underappreciated, and stage 5 CKD came to be interpreted by some as "time for dialysis." New information also became available, notably that albuminuria, not part of the 2002 NKF-KDOQI guideline CKD classification schema, was itself an independent predictor of important clinical outcomes and that a more precise degree of risk prediction became available as the result of innovative international research collaborations.
Thus, it became clear that a revision of the 2002 guideline was in order. The organization Kidney Disease: Improving Global Outcomes (KDIGO) convened a controversies conference in 2009 and subsequently organized an international work group to review and update the NKF-KDOQI CKD guideline. After the international KDIGO guideline was published in 2013, 2 NKF-KDOQI organized its own work group to provide a US-focused commentary on the KDIGO guideline. The yeoman efforts of this work group, led expertly by Drs Harold Feldman and Lesley Inker, are now presented in this commentary. The work group included experts in clinical nephrology, clinical epidemiology, and primary care medicine, and their many countless hours of volunteer work are much appreciated.
As has been stated many times, guidelines are guides to practice; they are not rules, they do not replace clinical judgment, they cannot anticipate patient preferences, and they are not able to speak to every conceivable clinical circumstance. They are also static, while medicine is not. Nonetheless, we believe that this NKF-KDOQI commentary will prove useful to physicians, nurses, and others involved in the care of patients with CKD.
INTRODUCTION
The NKF-KDOQI guideline for evaluation, classification, and stratification of CKD from 2002 defined CKD as an abnormality of kidney structure or function regardless of cause or specific clinical presentation and proposed a staging system based on the level of GFR. 1 The guideline also suggested a conceptual model for the natural history of CKD that often begins with initial kidney damage and progresses through the stages of CKD toward the outcome of kidney failure. During this progression, individuals are at an elevated risk of cardiovascular disease (CVD) and death. This conceptual model highlights the clinical value of early identification and management of patients with CKD and has promoted broad-based reporting of eGFR by clinical laboratories to maximize the detection of occult CKD. The KDOQI guideline was well accepted by the medical and public health communities and led to much change in clinical practice within the primary care, nephrology, and other specialty communities. 3 However, the KDOQI guideline also stimulated some controversies and questions. In particular, there have been concerns that use of its definition of CKD has caused excessive false identification of CKD and that its staging system was not sufficiently informative about prognosis. 4 In 2003, KDIGO was established with the mission "to improve the care and outcomes of kidney disease patients worldwide through the development and implementation of global clinical practice guidelines." 5 Prior to embarking on a new guideline, KDIGO often holds conferences to review outstanding questions and available evidence for the purpose of assessing whether a new practice guideline is warranted. KDIGO convened such a conference in 2009, with the goal of addressing the shortfalls of the KDOQI staging system. 6 Analyses performed for the purpose of this conference demonstrated that GFR and albuminuria are independent and complementary predictors of important clinical outcomes, including CKD progression, end-stage renal disease (ESRD), acute kidney injury (AKI), cardiovascular mortality, and all-cause mortality. [7] [8] [9] [10] On the basis of these and other data that have been reported since the publication of the original 2002 KDOQI guideline, KDIGO formed a work group to develop an updated CKD guideline for the international community. The specific goals of the KDIGO CKD guideline update were to clarify the definition and classification system of CKD and to develop appropriate guidance for the management of individuals with CKD. 2 The primary recommendations were to retain KDOQI's use of GFR as the principal basis for staging CKD, but to augment the staging scheme by incorporating cause of kidney disease and level of albuminuria in addition to level of GFR. The KDIGO guideline update contains a discussion of CKD progression, recommendations regarding referral to nephrologists, and management of the complications of CKD.
REVIEW AND APPROVAL PROCESS FOR THIS COMMENTARY
To assist US practitioners in interpreting the KDIGO guideline, the NKF-KDOQI convened a work group to write a commentary. The commentary addresses the full scope of the KDIGO guideline, focusing in particular on their relevance to and implementation in the United States. The NKF-KDOQI Steering Committee first selected Co-Chairs and then individual members based on their clinical and/or research expertise and interest in the guideline process. Individual sections focusing on each of the topic areas of the KDIGO guideline were drafted by groups of coauthors based on detailed review of each of the KDIGO chapters supplemented by additional literature review. All KDOQI commentary work group members conferred regularly by teleconference, and consensus among coauthors was achieved through discussion. A detailed discussion of the cost implications of the recommendations is not included in this commentary. This document was reviewed and approved by all coauthors and the KDOQI leadership.
The structure of this commentary aligns with the structure of the KDIGO guideline.
2 Numbered text within horizontal rules is quoted directly from the KDIGO document, using the same numbering scheme as in the original (all material is reproduced with permission of KDIGO). The text that follows, written by the commentary work group, comments on key guideline recommendations and discusses their implementation in the United States (see Box 1 for an overview).
DEFINITION AND CLASSIFICATION OF CKD
Definition of CKD 
Commentary
A formalized definition of CKD has provided great benefit to public health education efforts, research, and funding policies. The definition of CKD remains largely unchanged from previous guidelines, but has been clarified by the addition of "with implications for health," recognizing that not all abnormalities are similarly related to outcomes. The commentary work group concluded that not all structural or functional changes of the kidney have implications for health and that it is often not possible to accurately predict which patients will be negatively impacted. The classic example is the otherwise healthy kidney donor who has a GFR of 55 mL/min/1.73 m 2 . There are minimal implications for this person's health, but some medications may need dose adjustment and there may be side effects from long-term nonsteroidal anti-inflammatory drug (NSAID) usage. Finally, we concur with the criterion of kidney abnormalities being present for at least 3 months as a means of discriminating between chronic and acute disease, both in clinical practice and research studies. The duration of abnormalities has commonly been ignored in research studies. Staging of CKD 
Numerous studies in recent years have provided convincing evidence that both lower GFR and greater levels of albuminuria are independently related to mortality, cardiovascular events, and the rate of ESRD. As reviewed in the guideline, greater levels of
Box 1. Summary and Key Points
The commentary on Chapter 1 addresses the definition and classification of CKD, agrees with the addition of the albuminuria stages, but raises concerns about the incorporation of cause of disease into staging and also highlights issues regarding use of GFR estimation and albuminuria in clinical practice The commentary on Chapter 2 addresses the definition and identification of progression and highlights the limitation of the proposed definitions of CKD for assessing progression of kidney disease The commentary on Chapter 3 addresses the management of progression and complications of CKD, and highlights recommendations to lower blood pressure goals in the setting of proteinuria and the limited evidence supporting the impact of various components of lifestyle modification The commentary on Chapter 4 addresses cardiovascular disease risk and highlights the need for individualized decision making in some circumstances, and emphasizes that care of patients with progressive CKD should include multiple caregivers The commentary on Chapter 5, addressing the referral to specialists and models of care, highlights the need for individualized decision making in some circumstances, and that care of patients with progressive CKD should include multiple caregivers.
Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate.
Criteria for CKD (either of the following present for .3 months) Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate.
albuminuria are strongly predictive of outcomes at all levels of GFR at the individual and population levels. [6] [7] [8] [9] [10] Integrating both GFR and albuminuria into CKD staging paradigms will hopefully provide more precise classification and more accurate prognostic information. The commentary work group supports the addition of albuminuria into the classification scheme of CKD and characterization of the level of albuminuria by its severity (see last column in the table titled "Albuminuria categories in CKD"), rather than the terms microalbuminuria or macroalbuminuria.
We endorse the new distinction between CKD stage 3a (GFR of 45-59 mL/min/1.73 m 2 ) and 3b (GFR of 30-44 mL/min/1.73 m 2 ) in the updated guideline. As reviewed in the guideline, the risks of mortality and other outcomes vary greatly between these groups. The high prevalence of CKD stage 3 suggests that this distinction will have broad applications.
In contrast, the commentary work group views it premature to add cause of CKD to the classification scheme, although some specific causes have been related to faster rates of CKD progression and other health outcomes. Notably, there are currently no accurate methods to quantify risk based on cause of disease. The commentary work group considers that incorporating this information into the classification scheme could limit the ease of understanding and applicability of the classification scheme for referring physicians. (See chapter 5 of the KDIGO guideline for discussion of the inclusion as specific causes or unknown causes as reason for referral.)
The KDIGO guideline does not address screening for CKD among specific populations. However, we thought it would be worthwhile to comment on this topic given that the recent US Preventive Services Task Force recommendation highlighted the current lack of sufficient evidence to support CKD screening of asymptomatic adults. 11 A subsequent statement by the American College of Physicians (ACP) qualified these recommendations, saying that asymptomatic adults who are not at high risk for CKD should not be screened. The ACP went on to recommend not screening for proteinuria those individuals who are currently taking an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB). Separate guideline recommendations for patients with specific conditions placing them at higher risk of CKD (ie, diabetes or hypertension) suggest routine screening may be useful, but testing strategies and specific recommendations vary. 12, 13 The 2002 KDOQI guideline recommended assessment of the risk for developing CKD for all individuals, with measurement of blood pressure, albuminuria, and serum creatinine to estimate the GFR among those at higher risk. The commentary work group endorses the recommendations from the original guideline for screening among individuals at high risk for CKD despite the absence of this specific recommendation in the KDIGO guideline (Box 2), and as such is in agreement with the recommendation of the ACP to GFR categories in CKD Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate. *Relative to young adult level. In the absence of evidence of kidney damage, neither GFR category G1 nor G2 fulfill the criteria for CKD.
Albuminuria categories in CKD
Abbreviations: AER, albumin excretion rate; ACR, albumin-to-creatinine ratio; CKD, chronic kidney disease. *Relative to young adult level. **Including nephrotic syndrome (albumin excretion usually .2200 mg/24 hours [ACR . 2220 mg/g; .220 mg/mmol]).
screen asymptomatic adults only if they are at high risk for CKD. However, the commentary work group thought that information is gained from knowledge of the level of proteinuria beyond decisions to treat with an ACE inhibitor/ARB, such as prognosis and therefore disagrees with the ACP's recommendation to not screen individuals treated with ACE-inhibitor/ ARB agents. 
Commentary
This section focuses primarily on the aspects of evaluation of GFR and albuminuria that are relevant for clinicians. Although the guideline also discusses evaluation for chronicity and cause, the commentary work group agrees with these statements and does not have any additional comments.
Estimation of GFR from serum creatinine remains the clinical standard worldwide. Consistent with the original KDOQI CKD guideline, the KDIGO guideline emphasizes the importance of estimation of GFR rather than use of serum creatinine concentration alone.
1,2 The guideline also recognizes the limitations of creatinine and recommends additional confirmatory tests, such as measurement of cystatin C or clearance in situations when estimates of GFR from serum creatinine are less accurate.
The commentary work group agrees with the recommendation to use GFR estimating equations rather than creatinine alone for evaluation of kidney function. The commentary work group supports ongoing efforts to promote the use of specific creatinine assays calibrated to international standard reference materials with minimal bias compared to isotope-dilution mass spectrometry (IDMS) reference materials.
14 In addition, the commentary work group encourages the use of the CKD-EPI (CKD Epidemiology Collaboration) creatinine 2009 equation or other similarly accurate equations.
15
The KDIGO guideline also describes uses of cystatin C, alone or in combination with creatinine, to estimate GFR. The guideline does not state explicitly whether GFR should be estimated from cystatin C alone or in combination with creatinine. For the purposes of estimation of measured GFR, the combination of both markers provides a more precise estimate. [16] [17] [18] [19] For determination of prognosis and risk stratification, the evidence is less certain. 20 We agree with reporting both eGFR cys and eGFR cr-cys whenever cystatin C and creatinine are ordered so that the clinician can have both values of eGFR available for decision making.
The KDIGO guideline recommends measurement of cystatin C in persons with eGFR cr of 45-59 mL/ min/1.73 m 2 without albuminuria. The rationale for this statement is based on data showing that eGFR from creatinine may misclassify CKD and studies showing that GFR estimates using cystatin C in combination with creatinine improve classification of CKD based on measured GFR. 17 The guideline states that among persons with eGFR cr of 45-59 mL/min/ 1.73 m 2 without albuminuria and whose eGFR cr-cys and/or eGFR cys values are .60 mL/min/1.73 m 2 , the risk for CKD complications is very low. These persons could be considered not to have CKD. In addition, the guideline work group states that prediction of risk for future adverse events is improved with the use of cystatin C-based GFR estimates, as is supported by several studies, including a large meta-analysis published after the guideline; however, no specific recommendation was made by KDIGO. 20 We agree that GFR estimation using cystatin C alone or in combination with creatinine is useful as a confirmatory test of eGFR from creatinine, and that it improves risk stratification. However, many questions remain regarding how to incorporate cystatin C-based GFR estimates into practice. The KDIGO guideline mentions only one specific circumstance, but eGFR is used in multiple clinical settings on a routine basis and the guideline does not address most of these. For example, whether creatinine-or cystatin C-based estimates should be used to follow up patients longitudinally after the initial diagnosis is made remains unaddressed. In the commentary work group's opinion, assuming a patient remains clinically stable, it seems reasonable to use cystatin C-based eGFR estimates at subsequent time points, although there are no data to support this statement at this time. Implementation 1. Practical issues related to cystatin C measurement need to be considered prior to its introduction into the community at large. Notably, the price of testing is steadily decreasing, measurement is now automated, and it can be performed on existing platforms without the need for specialized equipment. More importantly, only cystatin C measurements obtained using assays traceable to higher level reference materials should be used to estimate the GFR.
2. The availability of measured GFR as a confirmatory test for eGFR from creatinine is limited by the lack of Current Procedural Terminology (CPT) codes for nonradioactive exogenous filtration markers, which precludes its financial viability. In addition, reference materials for nonradioactive iothalamate or iohexol are not available, further limiting their widespread use.
Evaluation of Albuminuria 1.4.4.1: We suggest using the following measurements for initial testing of proteinuria (in descending order of preference, in all cases an early morning urine sample is preferred) (2B); 1) urine albumin-to-creatinine ratio (ACR); 2) urine protein-to-creatinine ratio (PCR); 3) reagent strip urinalysis for total protein with automated reading; 4) reagent strip urinalysis for total protein with manual reading. 
Commentary
The guideline recommends urinary albumincreatinine ratio (ACR) in spot urine samples as the preferred measure rather than urine protein or albumin. The rationale for this recommendation is that ACR is a more sensitive and specific measure of kidney damage. Another motivation for this recommendation is that there are ongoing standardization efforts for urine albumin, whereas urine protein is more difficult to standardize. 21 The commentary work group agrees with this recommendation.
There are many factors that can affect urine protein or albumin temporarily. Some factors are related to specimen collection technique (eg, menstrual blood contamination) and others are related to numerous physiologic factors unrelated to renal function or injury (eg, exercise, urinary tract infection; shown in Table 1 ). Education of clinicians for these causes of variability in measured ACR levels other than changes in the level of kidney damage is necessary to promote appropriate interpretation of proteinuria data.
Because untimed urinary collections are difficult to standardize, concentrations of albumin or protein from such collections can be misleading. Measurement in the first morning urine is preferred because its protein concentration correlates well with 24-hour protein excretion and has relatively low intraindividual variability. Reporting of the albumin or total protein as a ratio indexed to the urine creatinine helps account for the variability in urinary albumin or total protein concentration measured in spot samples due to changes in urinary concentration. Assuming a creatinine excretion of 1 g/d, an ACR of 1,000 mg/g would translate to an albumin excretion rate (AER) of 1,000 mg/d. However, this assumption is not correct. Development of validated estimating equations for creatinine excretion that account for variation in urinary creatinine among people may be helpful to provide ACR or protein-creatinine ratio (PCR) values that are accurate estimates of total albumin or protein excretion. Last, we endorse the elimination of "microalbuminuria" and "macroalbuminuria" from the diagnostic testing lexicon. Implementation
Clinicians may be resistant to switching from urine protein to urine albumin since little evidence exists in the current medical literature for a difference in the value of these measures in predicting clinical outcomes. Educational efforts on the value of using urine albumin, in particular related to assay methodological issues, may be required. ). A certain drop in eGFR is defined as a drop in GFR category accompanied by a 25% or greater drop in eGFR from baseline. Rapid progression is defined as a sustained decline in eGFR of more than 5 ml/min/1.73 m 2 /yr. The confidence in assessing progression is increased with increasing number of serum creatinine measurements and duration of follow-up. 2.1.4: In people with CKD progression, as defined in Recommendation 2.1.3, review current management, examine for reversible causes of progression, and consider referral to a specialist. (Not Graded)
DEFINITION, IDENTIFICATION, AND PREDICTION OF CKD PROGRESSION

Definition and Identification of CKD Progression
Commentary
None of the recommendations in this chapter are graded. Despite having no evidence base, these recommendations have some face validity and address an important area, categorization of rates of kidney disease progression. We agree with the guideline statement that the frequency of estimating GFR and measuring albuminuria should increase with severity of Abbreviations: ACR, albumin-to-creatinine ratio; AKI, acute kidney injury; UTI, urinary tract infection. a Samples for urinary albumin (or total protein) measurement may be analyzed fresh, stored at 4 C for up to 1 week, or stored at 270 C for longer periods. Freezing at 220 C appears to result in loss of measurable albumin and is not recommended. When analyzing stored samples, they should be allowed to reach room temperature and be thoroughly mixed prior to analysis. 76 Reproduced with permission of KDIGO from. 2 disease. The commentary work group also agrees that it is important to recognize the inherent variability of creatinine when interpreting change in eGFR.
However, the commentary work group is concerned about the proposed magnitude of change in eGFR that signals disease progression for the following reasons. First, a definition based on percentage reduction of eGFR will differ across starting levels of eGFR and the duration of time over which the changes occur. For example, a 25% reduction in eGFR when beginning with levels such as 60 mL/min/1.73 m 2 would imply a loss of 15 mL/min/1.73 m 2 , a substantial loss of kidney function if it occurred over a relatively short time (eg, 2 years). Second, this amount of change is greater than the mean annual decline in eGFR found in any of the studies among individuals with CKD reported (Table 2 ) and is greater than the third criterion listed by the KDIGO guideline as indicating rapid progression ($5 mL/min/1.73 m 2 per year). Indeed, the evidence described in the KDIGO guideline from the Alberta Kidney Disease Network suggests that a decline of ,25% is also associated with increased risk of allcause mortality and ESRD (Table 3) .
2, [22] [23] [24] Third, changes in eGFR may be secondary to progression of CKD or superimposed AKI, and these often cannot be differentiated by considering a single value. Use of this stringent cutoff point for clinical decision making, such as referral as described in chapter 5 of the KDIGO guideline, may lead referring physicians to avoid 23, 24 Reproduced with permission of KDIGO from.
2 earlier and appropriate investigations of kidney disease. Albuminuria is central throughout the KDIGO guideline for the definition and staging of disease, and elsewhere in this chapter it is stated that assessment of albuminuria "should be undertaken to evaluate progression." 2(p65) Nevertheless, the severity of albuminuria or changes in albuminuria over time is not included in the proposed definition of progression. The KDIGO guideline justifies this by saying that there are no data to support specific cut points for change in albuminuria that are associated with kidney disease progression. The commentary work group agrees that changes in albuminuria should not be included in the definition of progression. However, if increases in albuminuria are not considered progression of CKD, the rationale for their measurement with a frequency similar to eGFR is not clear. The points made in chapter 1 of the KDIGO guideline about causes of variation in albuminuria are relevant here too when determining changes in albuminuria.
Regression of mild/moderate albuminuria is not uncommon, and discussion of how to evaluate remission of CKD with respect to both improvements in GFR and albuminuria is not included in the guideline. 
Predictors of Progression
Commentary
The commentary work group agrees with the KDIGO guideline about the key factors that inform prognosis. We also agree that prediction models may be a valuable tool, but they should be validated in a wide variety of clinical settings to ensure their generalizability prior to widespread use. Implementation
1.
It is important to differentiate between progression of chronic disease and acute injury. The definitions of each are different. As the definition of CKD progression is currently written, small changes in GFR could be consistent with AKI, whereas only large changes in GFR would indicate progressive CKD. However, small changes may be consistent with progressive CKD rather than AKI. Clinicians will need to attend to other clinical indicators to be able to accurately identify the cause of changes in GFR. Education of non-nephrologists as to how to differentiate these clinical entities will be challenging.
2. Change in eGFR may be due to true change in GFR or due to changes in the non-GFR determinants of creatinine concentrations, including assay fluctuations. Differentiating between these requires serial assessments and consideration of potential changes in the non-GFR determinants of creatinine. Education of non-nephrologists as to how to differentiate these clinical entities will be challenging.
3. Use of validated prediction models for progression of kidney disease may be able to incorporate numerous clinical factors and provide a single prognostic metric, which can guide decisions. Incorporation of such models into laboratory systems may facilitate their use. 
MANAGEMENT OF PROGRESSION AND COMPLICATIONS OF CKD
Commentary
Section 3.1 of the KDIGO guideline reviews the evidence in support of the recommendations aimed at delaying CKD progression. Recommendations for management of blood pressure were derived from the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD.
25 These recommendations are based on moderately strong evidence, with most of them falling between level 1B and 2D. The guideline encourages individualized targets based on age and tolerability of the chosen regimen and also provides specific blood pressure targets based on level of albuminuria and comorbid conditions. For example, the recommended target blood pressure for patients with CKD without albuminuria is #140/90 mm Hg, whereas it is #130/80 mm Hg for patients with albumin excretion $ 30 mg/24 h. This represents a departure from the target recommended by the 2004 KDOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in CKD, which recommended #130/80 mm Hg for all patients with CKD. 26 Overall, we agree with these recommendations, but also note that the blood pressure goal of #130/80 mm Hg for individuals with albuminuria is based on relatively low-quality evidence (2D). The panel members appointed to the Eighth Joint National Committee (JNC 8) recently released the 2014 evidence-based guideline for the management of high blood pressure in adults. 27 In patients with CKD, they recommend initiation of treatment for blood pressures . 140/90 mm Hg for patients of all ages without differentiation of targets by level of proteinuria. Higher quality evidence regarding the safety and efficacy of intensive blood pressure control will be forthcoming from the ongoing National Institutes of Health-sponsored Systolic Blood Pressure Intervention Trial (SPRINT), which includes a CKD subgroup.
28
The KDIGO guideline recommends an ACE inhibitor or ARB for patients with diabetes whose urinary albumin excretion is 30-300 mg/24 h and for all patients, with and without diabetes, whose urinary albumin excretion is .300 mg/24 h. We agree with the guideline-specific recommendations to use an ACE inhibitor or ARB and not the combination given the accumulating evidence of harm with combination therapy. 
Commentary
The guideline addresses dietary modifications and lifestyle changes in CKD. The commentary work group concurs with most of these recommendations with the following caveat. The recommendation to maintain a body mass index (BMI) of 20-25 kg/m 2 may be inappropriate for certain patients with CKD. Observational data suggest that the relationship between BMI and risk of adverse outcomes in CKD may be different from that in the general population. [34] [35] [36] Moreover, given the propensity for fluid retention in CKD, we thought that BMI may not accurately reflect body fat in this setting. 37 In addition, overly restrictive dietary prescriptions may diminish total caloric intake, markedly reduce protein intake, and result in malnutrition.
We agree with the ungraded statement that there is insufficient evidence to make recommendations for use of uric acid-lowering agents for the prevention of CKD progression.
Complications of CKD
COMPLICATIONS ASSOCIATED WITH LOSS OF KIDNEY FUNCTION
Definition and identification of anemia in CKD Although the recommendations in this section were not based on strong evidence, the commentary work group agreed with most of the guideline statements. We thought that there are insufficient data to endorse the recommendation to use markers of mineral metabolism in risk prediction models. Implementation 1. There are multiple recommendations made for the management of CKD and it may be challenging to implement all of them for any one patient. Approaching the recommendations in this chapter with some flexibility may allow clinicians to identify aspects of the guideline that may be more applicable to individual patients with CKD and to modify treatment strategies over the course of care. In addition, evidence is strongest for recommendations related to management of diabetes and hypertension, which often complicate CKD. Thus, it would be justifiable to first devote effort to setting blood pressure and glycemic goals, tailor antihypertensive and hypoglycemic therapies to individual patients, and monitor for side effects of the medications.
2. Because reduction in dietary sodium may facilitate achievement of blood pressure goals and the widespread use of sodium in the US food supply, Reproduced with permission of KDIGO from.
it seems reasonable to incorporate counseling on dietary sodium reduction into routine management of hypertension. However, achieving this goal is extremely difficult, in part because measurement of the sodium intake is not easy to implement, often requiring a 24-hour urine collection. In addition, access to expert dietary counseling may be a challenge for most US predialysis CKD care settings with the current billing and payment structure for allied health care professions, including dietitians. Population-level interventions, including modifications of sodium content in processed foods, will be required to effect substantive reductions in sodium intake.
40
OTHER COMPLICATIONS OF CKD
CKD and CVD 
Commentary
The increased risk of cardiovascular illness in the CKD population was highlighted in the 2002 KDOQI CKD guideline. 1 Since then, additional strong evidence has emerged in support of this relationship and several nontraditional CKD-specific risk factors for CVD have been identified. [41] [42] [43] Despite these findings, patients with CKD remain under-represented in interventional studies and as a consequence, the evidence basis for the recommendations related to cardiovascular risk reduction in CKD remains limited. Nonetheless, given the large burden of CVD in patients with CKD who have a high prevalence of traditional cardiovascular risk factors, we agree with the recommendation that risk-factor modification strategies recommended for the general population are indicated for patients with CKD. Additionally, the commentary work group believes that guideline 4.1.3 recommending antiplatelet therapy could have placed more emphasis on aspirin (acetylsalicylic acid) as initial therapy, the agent for which there is the strongest evidence of effectiveness in patients with CKD.
44,45
The evidence in support of CKD-specific therapeutic strategies for management of heart failure is similarly lacking. Indeed, most of the data reviewed by the guidelines for management of coronary heart disease in patients with CKD were derived from post hoc analyses of clinical trials outside of the setting of CKD. [46] [47] [48] [49] Given that these analyses demonstrate effectiveness of these therapies in the CKD population, the guideline recommends delivery of standard heart failure treatments for patients with CKD. We support these recommendations and also agree with the recommendation that any alterations in therapy should be accompanied by close monitoring of patients' GFR and potassium levels. Finally, we believe that the guideline should have placed greater emphasis on the risk for hyperkalemia and AKI associated with dual blockade of the reninangiotensin-aldosterone system (RAAS) 29,50-52 and recommend increased vigilance in monitoring of serum potassium and kidney function in these circumstances.
Caveats When Interpreting Tests for CVD in People With CKD
BNP/N-terminal-proBNP (NT-proBNP) 4.2.1: In people with GFR , 60 ml/min/1.73 m 2 (GFR categories G3a-G5), we recommend that serum concentrations of BNP/NT-proBNP be interpreted with caution and in relation to GFR with respect to diagnosis of heart failure and assessment of volume status. (1B) 
Commentary
The KDIGO guideline highlights the fact that cardiac biomarkers (B-type natriuretic peptide [BNP]/ N-terminal pro-BNP [NT-pro-BNP] and troponin) may be less reliable at lower levels of kidney function. These markers are inversely associated with level of GFR, suggesting that they may be filtered by the kidney and that higher levels would be derived from decreased filtration, at least in part, rather than exclusively from true cardiac damage. However, in CKD populations, BNP levels have been strongly associated with left ventricular hypertrophy and left ventricular dysfunction, even outside the setting of acute myocardial ischemia. [53] [54] [55] In addition, elevated concentrations of troponin T and troponin I by ultrasensitive assays have been associated with increased mortality. [56] [57] [58] The commentary work group acknowledges that the preponderance of literature examining cardiac testing in the setting of kidney disease focuses only on individuals with ESRD. Nevertheless, we agree with the KDIGO's emphasis on using the same diagnostic investigation for patients with CKD presenting with possible acute coronary syndrome as used for individuals without CKD. We agree that in the clinical context of chest pain, elevations of troponins must not automatically be attributed to reduced kidney function. Since these biomarkers may be elevated in the setting of CKD in the absence of acute ischemia due to chronic left ventricular wall stress, it is important to apply clinical judgment and evaluate trends in biomarker concentrations when engaging in clinical intervention. 
CKD and Peripheral Arterial Disease
Commentary
We agree with the KDIGO guideline that peripheral arterial disease is a serious and common problem in patients with CKD. However, we do not believe there is sufficient evidence to support a strategy of routine screening of this population with anklebrachial index. As acknowledged in the guideline, ankle-brachial index test results may have more limited value in CKD because of the high prevalence of calcified vasculature. Additionally, systematic screening has the potential to lead to adverse outcomes and increased costs as a consequence of additional testing (eg, angiography) and interventions. A more prudent approach might be to limit screening and testing to individuals with symptoms or signs of limb ischemia. 
Medication Management and Patient Safety in CKD
Commentary
Many commonly prescribed drugs or their metabolites are excreted by the kidneys and require dose adjustment to avoid potentially life-threatening complications. Furthermore, several commonly used drugs are nephrotoxic and may hasten progression of CKD or lead to AKI. Therefore, the guideline recommends drug dosing based on the level of GFR. Further, it recommends that individuals taking potentially nephrotoxic medications undergo close monitoring of their kidney function and discontinue drugs excreted by the kidneys or that are potentially nephrotoxic during periods of illness that predispose to AKI. We agree with the emphasis placed on drug dosing since this is often an under-recognized issue in the setting of CKD and has important implications for patient safety (Table 6 ). However, we were concerned about the recommendation to use cystatin C-based GFR estimates for drug dosing given uncertainty regarding direct effects of drugs on cystatin C generation.
The commentary work group agrees with the guideline's moderate approach to metformin dosing, which is consistent with recommendations recently published in the updated KDOQI guideline for diabetes and CKD. 30 The US Food and Drug Administration (FDA) had mandated a black-box warning for metformin that indicates it is contraindicated in patients with serum creatinine $ 1.5 mg/dL in men and $1.4 mg/dL in women based on the risk for lactic acidosis. However, some have questioned this warning and argued that it has prevented many individuals from benefitting from this drug. 59 It is now recognized that the risk for lactic acidosis in patients on metformin is extremely low, and the KDIGO guidelines reflects this new evidence. 60 
Imaging Studies
Commentary
We agree with these recommendations on the use of contrast agents in imaging studies. In particular, we also agree with the guideline recommendation to avoid gadolinium for people with GFR , 15 mL/min/ 1.73 m 2 versus ,30 mL/min/1.73 m 2 as is stated in the FDA's black box warning. 61 Notably, we also agree with the omission of a recommendation to not use N-acetylcysteine and/or sodium bicarbonate to prevent AKI caused by radio contrast media due to inconsistencies in the available evidence. 
CKD and Risks for
Commentary
We agree with the guideline that the benefits of immunization are far greater than the associated risks. If there are no contraindications, patients with CKD should receive the influenza vaccine annually and the pneumococcal vaccine with a booster vaccination every 5 years. 62 Newer vaccines recommended for the general population should also be administered to patients with CKD. As emphasized in the guideline, while the recommendations for hepatitis B vaccine are limited to patients with CKD who may undergo renal replacement therapy (RRT), all patients with CKD may benefit from vaccination if they have not been previously immunized or developed natural immunity from prior hepatitis B infection.
Compared to the original KDOQI CKD guideline, these KDIGO recommendations devote greater attention to the risk of AKI in patients with CKD and refer to the KDIGO AKI guideline for more specific recommendations. 63 This strong emphasis is a byproduct of the emergence of the large body of literature on AKI in CKD since the publication of the KDOQI CKD guidelines. The commentary work group agrees with this position.
Given insufficient data on specific causal mechanisms for the observed associations between CKD and risks of hospitalization and mortality, the guideline does not identify targeted interventions. Instead, a comprehensive approach to care for multiple comorbid conditions, especially CVD, is appropriately promoted as best clinical practice. The commentary work group agrees with this approach. 
Miscellaneous
Lithium Nephrotoxic and may cause renal tubular dysfunction with prolonged use even at therapeutic levels Monitor GFR, electrolytes, and lithium levels 6 monthly or more frequently if the dose changes or the patient is acutely unwell Avoid using concomitant NSAIDs Maintain hydration during intercurrent illness Risk-benefit of drug in specific situation must be weighed
Note: Data as of January 2013. Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; CKD, chronic kidney disease; GFR, glomerular filtration rate; IV, intravenous; KDIGO, Kidney Disease: Improving Global Outcomes; NSAIDs, non-steroidal antiinflammatory drugs; RAAS, renin-angiotensin-aldosterone system; SCr, serum creatinine.
Reproduced with permission of KDIGO from.
Implementation
1. The risks of complications of CKD, such as CVD, infections, AKI, and others discussed in this chapter, may be less well known to nonnephrologist providers. For example, in the case of CVD, educational efforts should be focused on primary care providers, emergency medicine physicians, nephrologists, and cardiologists. Education on immunizations in patients with CKD should focus mainly on primary care physicians, who are most likely to implement routine vaccinations.
2. Management of the increased cardiovascular risk will require coordination of care among providers. This issue is more fully explored in chapter 5 of the KDIGO guideline. For example, the need for additional peripheral arterial disease evaluation and interventions will require involvement of radiologists and vascular surgeons. Primary care providers will likely take on primary responsibility for managing CVD risk in patients with CKD, whereas nephrologists will often maintain a narrower focus on management of specific CKD-related issues (eg, resistant hypertension, mineral and bone disorders, and anemia).
3. Implementation will require the further development of electronic medical record systems to provide real-time alerts and guidance in drug dosing for patients with CKD. Reporting of eGFR in units of mL/min will also facilitate appropriate drug dosage adjustment by all providers and health care professionals.
4. Pharmacovigilance systems may also facilitate prevention of unsafe exposure to contrast agents and to oral phosphate-containing bowel preparations in individuals with GFR , 60 mL/min/1.73 m 2 .
REFERRAL TO SPECIALISTS AND MODELS OF CARE
Referral to Specialist Services The aim is to avoid late referral, defined here as referral to specialist services less than 1 year before start of RRT.
Commentary
Both of these recommendations were level 1 grade recommendations. These are common sense, clear, and actionable recommendations that should be straightforward for the primary care physician to implement. We agree that consideration of both GFR and albuminuria will guide appropriate referrals, thereby reducing problems of under-referral and late referral to nephrologists. We also agree that referral of all patients with CKD stage 4 or worse will promote interventions to delay progression and reduce CKD complications, as well as the ability to prepare for RRT. In contrast, the commentary work group questioned the appropriateness of referring all patients with ACR . 300 mg/g. Rather, the commentary work group thought that the decision to refer should be tailored to the specific needs of the patient and the provider's capacity to deliver specialty care. In the opinion of the commentary work group, 2 groups of patients who should be referred are those with side effects or contraindications to ACEinhibitor/ARB therapy, but albuminuria . 300 mg/g or nephrotic-range albuminuria or proteinuria. We suggest modifying the list above to add:
Questions about the etiology of albuminuria. Difficulty with decreasing level of albuminuria despite institution of ACE-inhibitor or ARB therapy.
We believe the recommendations to use validated prediction models for the development of kidney failure to guide timely referral for RRT is appropriate. The commentary work group notes that the current available prediction models are based on observational studies of patients in nephrology clinics who progressed to ESRD in non-US populations.
2 Prior to their widespread use, these or other models should be validated in other cohorts that are generalizable to the US population with CKD. Among certain subgroups of patients, the risk of death is higher than the risk of ESRD. 64, 65 If planning for RRT is not properly targeted to patients with a high enough risk of ESRD, then the costs and/or harms of this care might outstrip the benefits. 
The commentary work group agrees with KDIGO that dialysis initiation, for both peritoneal dialysis and hemodialysis, should not be based on estimates of kidney function alone, but should take into account symptoms and other complications of advancing kidney disease. We further recommend that the interpretation of symptoms be individualized with consideration of the expected benefit each patient may derive from starting dialysis. 
The KDIGO guideline presents 4 ungraded recommendations regarding the details of comprehensive conservative management. We agree with the goals of these recommendations, noting their consistency with practice guidelines on shared decision making from the Renal Physician's Association and the American Board of Internal Medicine/American Society of Nephrology "Choosing Wisely" campaign. 66, 67 However, these recommendations may be difficult to implement in the United States due to uneven access to palliative care across health care systems, a shortage of palliative-care physicians, limited training of US nephrologists in these areas, and poor reimbursement for these and other cognitive services. Implementation 1. Agreement for the coordination of referral to nephrologists and joint clinical management by primary care physicians, nephrologists, and other specialists should follow the principles of the patientcentered medical home, which is a paradigm whereby the relationships and communication among providers are specified and mechanisms exist for regular review of the agreement's effectiveness. Payment systems should promote this coordination of care by, for example, reimbursing for electronic or telephone communication among providers.
2. The elements of multidisciplinary care teams are present in many, but not all US health care systems and some payers may not reimburse for the services provided by nonphysician team members. For eligible patients with an eGFR of 15-29 mL/ min/1.73 m 2 , CKD education services are reimbursable through the Kidney Disease Education Benefit of the Medicare Improvements for Patients and Providers Act of 2008. However, this is not accessible to all patients due to copays and inconsistent implementation of education services across US nephrology practices.
3. With respect to the timing of dialysis initiation, a strategy of "watchful waiting" until the appearance of uremic symptoms represents a significant shift in US practice and has potential to result in significant cost savings for the health care system. Parity in the payment structure for dialysis management and advanced CKD management could facilitate redeployment of resources to safely manage patients in advanced CKD clinics.
4. Many US nephrology practices and health care systems are not equipped to incorporate recommendations concerning conservative management of advanced CKD into clinical practice. To facilitate the implementation of these recommendations, professional societies and accreditation organizations should emphasize training in palliative care for all nephrology providers. Payment reforms for palliative care services and adoption of quality metrics for palliative CKD care should also provide incentives to manage patients with advanced CKD who elect not to receive RRT. 68 
CONCLUSION
The KDIGO guideline recommendations on evaluation and management of CKD serve as an excellent summary of the state our knowledge and available evidence on CKD. Importantly, they provide an important and needed update to the staging system based on newly available data. They also highlight gaps in knowledge to guide future investigative efforts.
